Navidea Biopharmaceuticals, Inc. (NAVB)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Dec 26, 2024, 3:00 PM EST

NAVB Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2022 FY 2021 FY 2020 FY 2019 FY 2018 2017 - 2013
Period Ending
Dec '24 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 2017 - 2013
Market Capitalization
0730572319
Upgrade
Market Cap Growth
17.09%-77.52%-47.33%151.52%21.97%-67.87%
Upgrade
Enterprise Value
-2424412115
Upgrade
Last Close Price
0.000.211.002.151.262.05
Upgrade
PS Ratio
9.09103.2456.7362.5734.6015.96
Upgrade
PB Ratio
-3.01-0.8348.2627.97-25.847.74
Upgrade
P/TBV Ratio
---5.21-14.21
Upgrade
P/FCF Ratio
-----4.41
Upgrade
P/OCF Ratio
-----4.36
Upgrade
EV/Sales Ratio
7306.4265.3445.3244.9632.5512.82
Upgrade
EV/FCF Ratio
0.24----3.54
Upgrade
Debt / Equity Ratio
-0.42-0.301.200.65-1.210.13
Upgrade
Debt / FCF Ratio
-----0.07
Upgrade
Asset Turnover
0.000.010.070.150.120.08
Upgrade
Inventory Turnover
0.150.64----
Upgrade
Quick Ratio
0.490.200.821.200.591.45
Upgrade
Current Ratio
0.560.321.021.380.761.66
Upgrade
Return on Equity (ROE)
---878.18%-1839.18%-1431.29%-223.52%
Upgrade
Return on Assets (ROA)
-107.05%-129.93%-104.67%-112.43%-122.65%-43.82%
Upgrade
Return on Capital (ROIC)
---316.88%-374.92%-470.19%-71.13%
Upgrade
Earnings Yield
-26045.00%-223.93%-38.91%-18.73%-48.10%-86.35%
Upgrade
FCF Yield
-97293.63%-133.52%-33.97%-14.52%-41.10%22.66%
Upgrade
Buyback Yield / Dilution
-75.79%-5.31%-22.80%-66.02%-68.80%-2.72%
Upgrade
Total Shareholder Return
-75.79%-5.31%-22.80%-66.02%-68.80%-2.72%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.